Connectyx Technologies

What Connectyx Technologies does

Connectyx Technologies is a private US company founded in 1995, headquartered in Stuart, Florida, with 11-50 employees. Its stated positioning is the provision of healthcare-related intelligent software tools for the healthcare segment, indicating a software-driven approach to addressing needs within the healthcare market. The company is private and does not appear to have publicly disclosed pricing models, customer segments, or distribution channels in the available source material.

Substantive company content in the provided data is largely attributed to a related entity, Curative Biotechnology, Inc. (OTC ticker CUBT), a clinical-stage biotech focused on identifying, acquiring, and developing disease-modifying therapeutic drug candidates concentrated on rare/orphan disease indications. That entity's development pipeline covers Degenerative Eye Disease, Neuro Oncology, and Infectious Disease, with stated intent to eventually expand mechanisms of action into non-orphan indications. A Canadian patent allowance has been announced. Source material notes William E. Carlson as Chief Medical Officer & Board Member, and a recent board nomination of Dr. Theresa Heah. Given the ambiguity, Connectyx Technologies' revenue model, specific product surface, and customer base cannot be reliably characterized from the provided data.

Name

Connectyx Technologies

Legal name

Curative Biotechnology, Inc.

Website

https://connectyx.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Connectyx Technologies is a private US healthcare-focused software company founded in 1995 and headquartered in Stuart, Florida. It operates with 11-50 employees and provides intelligent software tools to the healthcare segment.

Ownership category

akta.pro rank

Headquarters

HQ city

Stuart

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Core offering

Connectyx Technologies provides a suite of healthcare-related intelligent software tools for the health care segment. The company is positioned as a software vendor serving healthcare customers with intelligent tool offerings. Specific product names, features, and modules are not detailed in the supplied source material.

Product overview

The provided source data does not contain information about Connectyx Technologies. The source content is about Curative Biotechnology, Inc. (ticker CUBT), a biotechnology company focused on identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Their development pipeline includes programs in Degenerative Eye Disease, Neuro Oncology, and Infectious Disease. Since the source data pertains to a different company entirely, no products or services for Connectyx Technologies can be extracted from this content.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Emerging players

• Disc Medicine: Disc Medicine is a clinical-stage rare-hematology biotech developing first-in-class therapeutics for rare blood disorders. It is comparable as a small-cap, clinical-stage rare-disease developer focused on novel mechanisms of action.
• ProQR Therapeutics: ProQR is a clinical-stage biotech developing RNA-based therapies for rare genetic disorders. As a similarly sized, similarly clinical-stage rare-disease peer, it provides a useful proxy for valuation benchmarks and partnership patterns for pre-revenue rare-disease companies.

Direct peers

• Amicus Therapeutics: Amicus is a rare-disease biotech developing disease-modifying treatments for conditions including lysosomal storage disorders. It is directly comparable on rare-disease focus and on the strategy of pursuing mechanisms that can extend across multiple rare and adjacent indications.
• Sarepta Therapeutics: Sarepta develops precision genetic medicines for rare neuromuscular diseases. Its experience building a rare-disease franchise and defending IP around novel mechanisms of action provides a directly relevant commercialization and IP template for Curative.
• Travere Therapeutics: Travere is a clinical-to-commercial rare-disease company with programs in rare kidney and metabolic disorders. It is a useful comparator for the trajectory Curative would need to follow to evolve from a clinical-stage micro-cap to a commercial rare-disease player.
• BioMarin Pharmaceutical: BioMarin is a commercial-stage rare-disease biotech with a focused portfolio of disease-modifying therapies. It is the most established pure-play rare-disease peer and serves as the primary strategic benchmark for valuation, pipeline breadth, and regulatory positioning for a company like Curative.
• Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapies for rare and ultra-rare diseases across multiple indications. Its multi-program rare-disease strategy closely mirrors Curative's intent to pursue several orphan assets in parallel.

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Alexion, now part of AstraZeneca, is the legacy leader in rare-disease therapeutics (e.g., Soliris). It represents the broad-incumbent ceiling — the type of large strategic acquirer that could ultimately partner with or acquire a multi-program rare-disease biotech like Curative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/1697602
• Xx.com/medflash1433
• Facebookfacebook.com/MedFlashPHR

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Connectyx Technologies